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Background. Nonalcoholic fatty liver disease (NAFLD) is one of the metabolic disorders presented in liver. The relationship
between severity of NAFLD and coronary atherosclerotic burden remains largely unknown. Methods and Materials. We analyzed
subjects undergoing coronary calcium score evaluation by computed tomography (MDCT) and fatty liver assessment using
abdominal ultrasonography. Framingham risk score (FRS) and metabolic risk score (MRS) were obtained in all subjects. A graded,
semiquantitative score was established to quantify the severity of NAFLD. Multivariate logistic regression analysis was used to
depict the association between NAFLD and calcium score. Results. Of all, 342 participants (female: 22.5%, mean age: 48.7 ± 7.0
years)metthesuﬃcientinformationrenderingdetailedanalysis.TheseverityofNAFLDwaspositivelyassociatedwithMRS(X2 =
6.12, trend P<0.001) and FRS (X2 = 5.88, trend P<0.001). After multivariable adjustment for clinical variables and life styles,
the existence of moderate to severe NAFLD was independently associated with abnormal calcium score (P<0.05). Conclusion.
The severity of NAFLD correlated well with metabolic abnormality and was independently predict coronary calciﬁcation beyond
clinicalfactors.OurdatasuggeststhatNAFLDbasedonultrasonogramcouldpositivelyreﬂecttheburdenofcoronarycalciﬁcation.
1.Introduction
Atherosclerosis is the most common vascular pathology in
patients with cardiovascular events, which leads to mortality
in developed countries. There are various tools to evaluate
the diseased populations for prediction, diagnosis, and risk
stratiﬁcation. Among asymptomatic patients, the predictive
and prognostic values of calcium scores via electron beam
computed tomography (EBCT) were proved in previous
studies, either as an addition to the FRS or to C-reactive pro-
tein [1], or used alone [2]. Because coronary calciﬁcation is
not uncommon in patients with myocardial ischemia, mul-
tidetected computed tomography (MDCT) has become a
more useful modality for coronary heart disease evaluation.
On the other hand, evolving evidence showed that NAFLD
may actually represent metabolic syndrome in liver [3].
The existence and severity of NAFLD by liver biopsy as
a gold standard also proved to be association with MRS
[4, 5]. Recent studies demonstrated that NAFLD could
further predict cardiovascular diseases or even involved the
pathophysiologic process of atherosclerosis [4].
In our study, we sought to deﬁne the correlation between
the extent of NAFLD, cardiovascular risks, and MDCT-
acquired calcium score. We also tried to examine the role of
NAFLD beyond other clinical factors in the prediction and
identiﬁcation of coronary calciﬁcation.2 Radiology Research and Practice
2.MaterialsandMethods
2.1. Study Subjects. We subsequently enrolled 342 non-
alcoholism from outpatient clinics or subjects underwent
health evaluation who had both MDCT examination for
cardiovascular risk stratiﬁcation as well as abdominal ultra-
sonography for the detection of fatty liver disease. This study
was proved by the ethics committee of Mackay Memorial
Hospital,Taipei,Taiwan(09MMHIS038),inaccordancewith
the Declaration of Helsinki.
2.2. Data Collection and Laboratory Parameters. Anthropo-
metric measurements including body height, body weight,
waist circumference, and blood pressures at rest were taken
by a registered technician who was blinded to the other
test results. Body mass index (BMI) was derived from the
r a t i oo fw e i g h tt oh e i g h ts q u a r e d .B o d ys u r f a c ea r e a( B S A )
was calculated according to formula of DuBois. Review of
medicalhistory,physicalexamination,12-leadelectrocardio-
gram,andchestplainﬁlmwereallperformedbystudyphysi-
cians. High-sensitivity C-reactive protein (hs-CRP) levels
were determined by a latex particle-enhanced immunoassay
using Elecsys 2010 method (Roche, Mannheim, Germany).
The other laboratory data, including a lipid proﬁle and a
renal function test, was obtained by a Hitachi 7170 Au-
tomatic Analyzer (Hitachi Corp. Hitachinaka Ibaraki,
Japan). Immunoreactive insulin was measured by radioim-
munoassay (PerkinElmer Automatic Gamma Counter 1470;
PerkinElmer, Waltham, MA, USA). Insulin resistance was
further deﬁned as using the following homeostasis model
equation: insulin resistance method (HOMA-IR) = fasting
glucose (mmol/L) × fasting insulin (μU/mL)/22.5. HbA1c
level was obtained by high-performance liquid chromatog-
raphy (Bio-rad Variant II; Bio-Rad Laboratories, Hercules,
CA, USA). Body fat composition percentage was assessed by
using a commercialized foot-to-foot bioelectrical impedance
scale (Tanita Inc., Tokyo, Japan, models TBF 410GS).
2.3. Abdominal Ultrasonography for NAFLD Grading. Ab-
dominal ultrasonography is a validated tool to diagnose fatty
liver rather than liver biopsy. The presence of fatty liver
disease was detected using abdominal ultrasonography done
by an experienced gastroenterologist who has no reference
of the participants’ other data. Three levels adopted for
evaluating the severity of fatty liver was based on 4 basic
techniques (hepatorenal echo contrast, liver brightness, deep
attenuation, and vascular blurring) as described from previ-
o u ss t u d i e s[ 6]. Right kidney echogenicity was used for the
contrast of liver parenchyma echogenicity. It is normal with
the same kidney cortex and liver parenchyma echogenicity.
The severity of NAFLD is graded as the following: mild:
minimal diﬀuse increase in liver brightness, but diaphragm
and intrahepatic vessel contours seem normal; moderate:
medium grade diﬀuse increase in liver brightness and mild
attenuation of diaphragm and intrahepatic vessels; severe:
apparent increase in echogenicity. Under the aware that
fatty liver interpretation by using ultrasonic assessment may
be subjective, we adopted a more strict methodology in
categorizing subjects with at least moderate degree fatty liver
disease as signiﬁcant fatty liver disease in this study.
2.4. Coronary Calcium Score Measurement. Coronary cal-
ciﬁcation of coronary arteries was quantiﬁed by using a
dedicated oﬄine workstation (Aquarius 3D Workstation,
TeraRecon,SanMateo,CA,USA).Acoronarycalciﬁedlesion
was deﬁned as an area with a density >130 HU and covering
atleast6pixels.Scanningwasperformedbya16-sliceMDCT
scanner (Sensation 16, Siemens Medical Solutions, Forch-
heim, Germany) with 16 × 0.75mm collimation, rotation
time 420ms, and tube voltage of 120kV in one breath hold.
From the raw data, the images were reconstructed with
standard kernel in 3mm thick axial, nonoverlapping slices
and 25cm ﬁeld of view. The Agatston score method was
applied by multiplying each lesion (area) by a weighted CT
attenuation score in the lesion.
2.5. Deﬁnition of Framingham Risk Score. The Framingham
risk score (FRS) is designed to estimate 10-year risk of
developing coronary heart disease (myocardial infarction
and coronary death) in adults aged 20 and older who do
not have heart disease or diabetes. This tool is based on the
score (Adult Treatment Panel III, ATP-III) deriving from the
information of age, gender, cholesterol dysregulation, (pre)
hypertension, and smoking [7].
2.6. Deﬁnition of Metabolic Risk Score. Similar to ATP-III
criteria, abnormal metabolic components deﬁned by the
Bureau of Health Promotion, Department of Health, Taiwan
were [8]: (1) increased waist circumference of at least 90cm
in men and of at least 80cm in women; (2) abnormally
elevated serum triglycerides (TG) of at least 150mg/dL;
(3) lower serum high-density lipoprotein (HDL) cholesterol
of less than 40mg/dL for men and less than 50mg/dL
for women; (4) higher fasting blood glucose level greater
than 110mg/dL; (5) elevated systolic blood pressure of
at least 130mmHg and/or diastolic blood pressure of at
least 85mmHg, or undergoing hypertension treatment. The
scoring system was calculated and presented as the numbers
of abnormal items meeting the criteria, with score 0 for
the absence and score 5 for the presence of all 5 abnormal
metabolic components. Metabolic risk score (MRS) of 3 or
more met the deﬁnition of metabolic syndrome.
2.7. Statistics. All data was presented as mean ± SD. Con-
tinuous data between groups with and without abnormal
calcium score deposition were compared by using Mann-
Whitney test with abnormal distribution and by Student
t-test if in normal distribution. Categorical variables were
compared by Chi square and Fisher Exact tests as appro-
priate. Nonparametric rank sum test was used to test the
graded change of cardiovascular risks estimated by using
ATP III or Framingham system over diﬀerent fatty liver
status. Multivariable regression model was used based on
Framingham system (FRS) and ATP III (MRS) with life
styles or other variables not included in the Framingham
system (FRS) or ATP III (MRS) model sequentially enteredRadiology Research and Practice 3
Table 1: Baseline demographic data and clinical information in our study.
Calcium score zero (N = 239) Calcium score abnormal (N = 103) P value
Age, years 47.0 (6.4) 52.6 (6.6) <0.001
Gender, female % 66 (27.6) 11 (10.6)
Height, cm 165.9 (7.5) 167.7 (7.5) 0.09
Weight, kg 65.9 (11.3) 68.9 (10.1) 0.008
BMI, Kg/m2 23.8 (3.1) 24.4 (2.7) 0.013
Waist, cm 81.4 (9.1) 85.0 (7.9) <0.001
Waist to hip ratio 0.88 (0.07) 0.91 (0.06) <0.001
SBP, mmHg 116.7 (14.9) 125.1 (15.1) 0.003
DBP, mmHg 74.5 (10.2) 77.9 (9.7) 0.002
Biochemistry
Sugar (AC), mg/dL 93.3 (21.2) 102.0 (20.9) 0.086
Sugar (PC), mg/dL 105.9 (31.6) 118.5 (44.4) 0.082
HbA1c, % 5.8 (0.6) 6.0 (0.6) 0.32
Insulin, U/mL 6.25 (4.24) 6.91 (3.75) 0.046
HOMA-IR 1.55 (1.25) 1.76 (1.06) 0.016
Cholesterol, mg/dL 191.1 (32.9) 196.1 (35.1) 0.23
LDL, mg/dL 128.0 (31.3) 125.8 (31.7) 0.56
HDL, mg/dL 53.0 (13.7) 49.1 (12.8) 0.02
TG, mg/dL 141.9 (103) 145.8 (85.2) 0.74
BUN, mg/dL 11.8 (3.2) 12.6 (3.7) 0.32
Creatinine, mg/dL 0.91 (0.18) 0.97 (0.18) 0.39
Uric Acid, mg/dL 5.6 (1.4) 6.1 (1.5) 0.003
Homocystine, mg/dL 7.3 (2.1) 8.4 (2.3) 0.03
Hs-CRP, mg/dL 0.2 (0.35) 0.32 (0.7) 0.043
ECG pattern
ECG (LVH or myocardial ischemia) 41 (7.5) 28 (13.2) 0.016
ECG (old infarct) 5 (1) 9 (4.2) 0.002
Medical history
Smoking 84 (24.9) 42 (29.4) 0.311
HTN history 41 (12) 35 (23.7) 0.001
DM history 11 (3.2) 14 (9.5) 0.004
Hyperlipidemia 17 (5.6) 13 (9.6) 0.039
CVD 12 (3.9) 12 (8.9) 0.033
Family Hx
Family Hx HTN 147 (43) 62 (41.9) 0.823
Family Hx DM 88 (25.8) 42 (28.4) 0.554
Family Hx Stroke 49 (14.3) 20 (13.5) 0.812
Family Hx CVD 57 (16.7) 30 (20.3) 0.345
BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; sugar (AC): fasting glucose; sugar (PC): postprandial glucose; HOMA-IR:
insulin resistance; ECG: electrocardiography; LVH: left ventricular hypertrophy; HTN: hypertension; DM: diabetes; NAFLD: nonalcoholic fatty liver disease;
CVD: cardiovascular disease: Hx: history.
to identify the independent value in predicting fatty liver
disease. Receiving operative characteristic (ROC) curves
were used to test the hypothesis that whether the existence
of NAFLD helps provide incremental value in the detection
ofabnormalcoronarycalciumdeposition beyondtraditional
cardiovascular risk systems. P value was set at two-tailed
probability, and a P v a l u el e s st h a n0 . 0 5w a sc o n s i d e r e d
statistically signiﬁcant. All analysis was done by the software
package STATA 8.2 (StataCorp, College Station, TX, USA).
3. Results
3.1. Patients Demographics and Baseline Characteristics. Of
all 342 participants, 239 subjects (mean age 47 years, 27.6%
female) did not have notable calciﬁcation of all coronary
territories (Group I), whereas 103 subjects (mean age 52.6
years, 10% female) were with obvious coronary calciﬁcation
(GroupII).Maindemographicdataandbaselinecharacteris-
ticsareillustratedinTable 1.Subjectswithabnormalcalcium4 Radiology Research and Practice
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Figure 1: Estimated cardiovascular risk scores and coronary calciﬁcation categorized by the severity of nonalcoholic fatty liver disease. More
severe fatty liver disease was associated with higher cardiovascular risk scores by either metabolic or Framingham risk scores and coronary
calcium scores.
scores(GroupII)wereolderwithmoremalegender.Inaddi-
tion, they tended to have larger BMI, waist circumference,
and higher blood pressure. Baseline biochemistry did not
show signiﬁcant diﬀerences between these two groups except
a trend toward higher serum glucose level. MRS and FRS
were also higher in group II. The prevalence of abnormal
electrocardiographic patterns like ischemia or hypertrophy
was higher in group II. Subjects in group II were also
observed to have higher prevalence of hypertension, diabetes
or hyperlipidemia medical history when compared with
group I.
3.2. The Independent Predictive Value of NAFLD in Diﬀerent
Models. In Figure 1, we illustrated the relationship between
coronary calcium score, cardiovascular risk scores, and the
degree of fatty liver echogenicity. More severe fatty liver
degree was observed to be associated with higher calcium
scores, higher FRS and MRS (trend P<0.001). We
further examined the independent value of NAFLD in the
prediction of abnormal coronary calcium scores by testing
diﬀerent clinical variables based on FRS or MRS separately
into three diﬀerent models (Table 2). In model 1, when
other clinical variables including smoking and exercise based
on the relatively insuﬃciency of individual scores were
entered into regression model, signiﬁcant fatty liver disease
independentlyidentiﬁedcoronarycalciumexistenceineither
FRS group or the MRS group. In model 2, when liver func-
tion tests were together in regression model, moderate to
severe fatty liver disease was still independently associated
in both groups. In model 3, when body fat composition was
further entered in the regression model, the presence of fatty
liver disease remained statistically signiﬁcantly independent
in the prediction of coronary calcium existence.
3.3. The Incremental Value of NAFLD beyond Traditional
Cardiovascular Risks in the Prediction of Coronary Calcium
Scores. In Figure 2,wetested thehypothesis thatwhetherthe
presence of fatty liver disease could further expand the area
under curve (AUC) for the discrimination of coronary artery
calciﬁcation from normal subjects meaningfully. While FRSRadiology Research and Practice 5
Table 2: Multivariate logistic regression models in predicting coronary calcium deposition.
Variables OR SE ZP CI 95%
Model 1
FRS 1.16 0.05 3.09 0.002 1.054599 1.268832
BMI 0.93 0.06 −1.23 0.218 .8193498 1.04653
Sugar (AC) 0.99 0.01 −0.5 0.618 .9744172 1.015514
Drinking 0.99 0.39 −0.02 0.981 .4557979 2.153525
Exercise 0.76 0.63 −0.33 0.742 .1488091 3.882643
Fatty liver (moderate to severe) 4.47 2.66 2.52 0.012 1.393377 14.33824
DM history 1.92 2.15 0.58 0.563 .2114827 17.35303
MRS 1.1 0.15 0.67 0.506 .836501 1.436341
Age 1.16 0.03 5.16 <0.001 1.097237 1.229447
Sex 4.84 2.62 2.92 0.004 1.677794 13.97886
Drinking 0.7 0.28 −0.88 0.381 .3176925 1.549465
Smoking 0.8 0.36 −0.49 0.627 .3329831 1.94089
Exercise 0.32 0.3 −1.21 0.225 .0488721 2.032724
Fatty liver (moderate to severe) 3.83 2.13 2.42 0.016 1.288897 11.39297
Model 2
FRS 1.15 0.06 2.87 0.004 1.045555 1.26785
BMI 0.92 0.06 −1.18 0.24 .811891 1.053551
Sugar (AC) 0.99 0.01 −0.71 0.478 .9715331 1.013632
Drinking 0.77 0.33 −0.61 0.544 .3299596 1.794328
Exercise 0.78 0.67 −0.29 0.772 .145282 4.191667
Fatty liver (moderate to severe) 7.36 5.35 2.75 0.006 1.769904 30.56831
DM history 1.71 2 0.46 0.649 .1713221 16.99859
Viral hepatitis carrier 1.14 0.65 0.23 0.82 .3714342 3.491325
GPT 0.99 0.01 −0.92 0.359 .9695872 1.011263
rGT 1.02 0.01 1.1 0.272 .9879836 1.043843
MRS 1.06 0.16 0.37 0.71 .7835745 1.43072
Age 1.16 0.03 4.93 <0.001 1.092158 1.226692
Sex 5.19 2.9 2.95 0.003 1.737443 15.52867
Drinking 0.58 0.25 −1.26 0.207 .2466988 1.353505
Smoking 0.8 0.38 −0.47 0.641 3155051 2.035192
Exercise 0.29 0.27 −1.31 0.19 .0437895 1.8624
Fatty liver (moderate to severe) 7.43 4.95 3.01 0.003 2.014803 27.42179
Viral hepatitis carrier 1.34 0.77 0.51 0.613 .4322222 4.144012
GPT 0.98 0.01 −1.41 0.159 .9619023 1.006359
rGT 1.01 0.01 1.01 0.312 .9861562 1.044676
Model 3
FRS 1.14 0.05 2.78 0.005 1.040021 1.253657
BMI 1 0.08 0.1 0.921 .8635472 1.176196
Sugar (AC) 0.99 0.01 −0.67 0.505 .9722974 1.013941
Drinking 0.73 0.32 −0.74 0.461 .3102782 1.70035
Exercise 0.4 0.39 −0.94 0.347 .0574678 2.726738
Fatty liver (moderate to severe) 6.77 4.95 2.62 0.009 1.61448 28.35676
DM history 1.46 1.68 0.33 0.743 .1532743 13.87366
Viral hepatitis carrier 1.31 0.77 0.47 0.641 .418516 4.118456
GPT 0.99 0.01 −0.87 0.385 .9708703 1.011461
rGT 1.02 0.01 1.03 0.302 .9870173 1.043093
Body fat 0.92 0.04 −1.94 0.053 .8456979 1.0009796 Radiology Research and Practice
Table 2: Continued.
Variables OR SE ZP CI 95%
MRS 1.12 0.18 0.72 0.473 .8203864 1.532548
Age 1.16 0.03 4.97 <0.001 1.092734 1.226381
Sex 3.1 2 1.76 0.078 .8790155 10.95577
Drinking 0.58 0.25 −1.25 0.211 .2463022 1.363246
Smoking 0.83 0.4 −0.38 0.702 .3256642 2.129526
Exercise 0.18 0.18 −1.75 0.08 .0260914 1.227528
Fatty liver (moderate to severe) 8.58 6 3.07 0.002 2.176022 33.82722
Viral hepatitis carrier 1.44 0.84 0.63 0.528 .4627544 4.488757
GPT 0.99 0.01 −1.17 0.243 .9656288 1.008901
rGT 1.02 0.02 1.04 0.298 .9864816 1.045414
Body fat 0.94 0.04 −1.57 0.117 .8679529 1.015836
FRS: Framingham risk score; MRS: metabolic risk score; γ-GT: γ-glutamyl transpeptidase; GPT: alanine aminotransferase. Other abbreviations were listed in
Table 1.
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Figure 2: Receiver operating characteristic curves demonstrated by both metabolic or Framingham risk scores and superimposed by fatty
liver disease in predicting coronary calcium deposition. When presence of fatty liver disease was added on traditional cardiovascular risk
scores, there was signiﬁcant increase in the area under curve.
andMRSalonehaveanAUCof0.67and0.64,theadditionof
NAFLD further signiﬁcantly expanded the AUC to 0.71 and
0.69, respectively (c-statistics < 0.05).
4. Discussion
In this study, anthropometric data from asymptomatic
people without known cardiovascular disease demonstrated
a signiﬁcantly positive correlation between coronary cal-
cium score and traditional anthropometrics, blood pressure,
insulin resistance, and systemic inﬂammation marker in
terms of hs-CRP. Both estimated cardiovascular risk scores
including FRS and MRS for the prediction of coronary calci-
ﬁcation in our study by utilizing ROC analysis were similar
to that in Wanamethee’s report [9]. However, unique to this
study, we found that more severe fatty liver disease, when
assessed by abdominal ultrasonography, may serve as an
independentfactorevenafteradjustmentofclinicalvariables
and estimated cardiovascular risk scores. Furthermore, we
also demonstrated that the presence of more severe degreeRadiology Research and Practice 7
fatty liver disease added incremental value beyond such
traditional cardiovascular risks in the prediction of coronary
artery calciﬁcation.
Atherosclerosis, conceptualized as a convergence of bone
biology with vascular inﬂammatory pathobiology [10], can
recently be assessed and quantiﬁed by extent of coronary
artery calciﬁcation in terms of coronary calciﬁcation score
when EBCT was clinically introduced and started to serve as
a feasible surrogate marker [11–13]. Higher calcium scores
are seen in most patients with myocardial ischemia, either
symptomatic or silent [2, 14]. And the result of coronary
calcium score derived from EBCT also predicts stress-
related ischemia on stress nuclear images [14]a n df u t u r e
cardiovascular events [2].
Metabolic syndrome as a medical disorder complex with
a central key factor of obesity accompanied with insulin
resistance has been proved as an antecedent of types of
diabetes mellitus and several cardiovascular diseases [9, 15–
20]. Another frequently used cardiovascular risk estimate
such as Framingham score is also a widely accepted scoring
system,usingage,smoking,HDL,BP,andcholesterolinstead
of triglyceride, in predicting cardiovascular risks [1, 9].
The ATP III had suggested usage of both the metabolic
risk factors plus Framingham score in determining the
risk of cardiovascular events and targeting treatment goal
of LDL. It is thus not surprising that NAFLD, deﬁned
as excess fat accumulation in the fat-laden hepatocytes by
light microscopy which covers a broad clinical spectrum of
liver diseases, be viewed as a component or consequence of
metabolic syndrome [21, 22]. However, this “gold standard”
is not clinically feasible in daily practice. In the recent years,
liver ultrasound has emerged as the most common and
simplest one of the alternative tools in NAFLD diagnosis
[23].
In contrast to Caucasian, the Asian populations have
shownhigherprevalenceofnonalcoholicsteatohepatitisthan
alcoholichepatitiswithnearly33%ofNAFLDmeetthecom-
plete diagnosis of metabolic syndrome [24]. In this regard,
NAFLD has thus been deemed a hepatic representation of
metabolic syndrome [3].
Recent studies have demonstrated that NAFLD patients
had developed subclinical atherosclerosis when compared to
nonsteatosis individuals. Further, cardiovascular disease is
the second most common cause of death in NAFLD patients
[4]. More importantly, subjects with known steatosis are
associated with abnormal carotid intima-media [25], more
vulnerable coronary plaques by MDCT [26], higher serum
markers of inﬂammation [27], worse endothelial func-
tion, increased myocardial insulin resistance [28], decreased
adiponectin concentrations, and abnormal lipoprotein me-
tabolism [29–31].
Ethnic diﬀerences in MESA study, such as higher per-
centage of coronary calciﬁcation in Chinese than Hispanic
and black groups, was suggestive of unknown mechanism
inﬂuencing cardiovascular diseases [32]. So far, it remains
inconclusive and controversial regarding the true causal rela-
tionship between NAFLD and cardiovascular diseases. Some
studies had ever described that NAFLD is less likely a direct
mediator of cardiovascular disease but an “epiphenomenon”
[33]; however, our study reported the independent role of
NAFLD in predicting coronary calciﬁcation beyond tradi-
tional cardiovascular scores. This ﬁnding may have an im-
pact on cardiovascular risk stratiﬁcation or even disease
process evaluation. More severe form of NAFLD could thus
be viewed as an independent clinical marker for higher
cardiovascular risks that may beneﬁt from a more aggressive
approach. It also deserves more eﬀorts to work out the
inﬂuence of liver fat intervention on cardiovascular diseases
compared to prior reports [34, 35].
5. Conclusion
The severity of NAFLD not only links to metabolic derange-
ment and traditional cardiovascular risks but also inde-
pendently identiﬁes the burden of coronary atherosclerosis
in terms of coronary calciﬁcation. Simple NAFLD grading
by liver ultrasonography may serve as a clinically useful
tool beyond conventional risk factors in cardiovascular risk
stratiﬁcation.
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